CIK 0001501697 · Non-accelerated filer<br>Smaller reporting company
X4 Pharmaceuticals, Inc
Sign in to watch- Ticker
- XFOR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273181608
- Phone
- 857-529-8300
- Business address
- 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134
- Former names
- Arsanis, Inc.
- Open-market buys, last 90 days
- $11,884
- in 1 filing
- Open-market sales, last 90 days
- $33,658
- in 1 filing
Net −$21,775. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-13 | Baldry Mark Chief Commercial Officer | Grant or award · Stock Appreciation Right | +523,414 | 523,414 | ||
| 2024-02-13 | Taveras Arthur Chief Scientific Officer | Grant or award · Stock Appreciation Right | +428,248 | 428,248 | ||
| 2024-02-12 | DiBiase Mary Chief Operating Officer | Sale | −3,683 | $1.01 | $4K | 307,161 |
| 2024-02-12 | Taveras Arthur Chief Scientific Officer | Sale | −787 | $1.01 | $793 | 248,536 |
| 2024-02-12 | Ragan Paula President and CEO | Sale | −21,695 | $1.01 | $22K | 814,746 |
| 2024-02-12 | Mostafa Adam S. Chief Financial Officer | Sale | −27,721 | $1.01 | $28K | 52,500 |
| 2023-11-03 | Ragan Paula President and CEO | Sale 10b5-1 | −39,906 | $0.90 | $36K | 836,441 |
| 2023-11-01 | Ragan Paula President and CEO | Sale 10b5-1 | −199,531 | $0.73 | $146K | 876,347 |
| 2023-11-01 | Mostafa Adam S. Chief Financial Officer | Sale 10b5-1 | −230,645 | $0.73 | $168K | 80,221 |
| 2023-11-01 | DiBiase Mary Chief Operating Officer | Sale 10b5-1 | −67,695 | $0.73 | $49K | 310,844 |
| 2023-11-01 | Baldry Mark Chief Commercial Officer | Sale 10b5-1 | −10,257 | $0.73 | $7K | 24,690 |
| 2023-11-01 | Taveras Arthur Chief Scientific Officer | Sale 10b5-1 | −67,695 | $0.73 | $49K | 249,323 |
| 2023-10-31 | Mostafa Adam S. Chief Financial Officer | Grant or award | +230,645 | 310,866 | ||
| 2023-10-31 | Baldry Mark Chief Commercial Officer | Grant or award | +34,947 | 34,947 | ||
| 2023-10-31 | Taveras Arthur Chief Scientific Officer | Grant or award | +230,645 | 317,018 | ||
| 2023-10-31 | Ragan Paula President and CEO | Grant or award | +532,081 | 1,075,878 | ||
| 2023-10-31 | DiBiase Mary Chief Operating Officer | Grant or award | +230,645 | 378,539 | ||
| 2023-10-16 | Woods Keith Director | Grant or award | +90,000 | 90,000 | ||
| 2023-09-08 | DiBiase Mary Chief Operating Officer | Sale | −2,642 | $1.25 | $3K | 147,894 |
| 2023-08-31 | Arbet-Engels Christophe Chief Medical Officer | Grant or award · Stock Option (right to buy) | +1,250,000 | $1.28 | $1.6M | 1,250,000 |
Page 5 of 6 · 120 trades